Coexistence of raynaud's phenomenon and chronic active hepatitis with hepatitis B antigen.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000328:Adult; D001323:Autoantibodies / Q000032:analysis; D001706:Biopsy; D002908:Chronic Disease; D006506:Hepatitis A / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D006511:Hepatitis B Antigens / Q000032:analysis; D006801:Humans; D007122:Immunoelectrophoresis; D008099:Liver / Q000382:microbiology; D008297:Male; D010643:Phenoxybenzamine / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011928:Raynaud Disease / Q000150:complications* / Q000188:drug therapy / Q000276:immunology
D000317:Adrenergic alpha-Antagonists; D001323:Autoantibodies; D006511:Hepatitis B Antigens; D010643:Phenoxybenzamine; D011241:Prednisone